Discovery of potent PROTAC degraders of KRASG12C based on a reversible non-covalent KRAS binder

被引：1
|
作者：
Zhang, Z. [1 ]
Zhai, W. [1 ]
Chen, H. [1 ]
Wang, L. [1 ]
Liu, D. [1 ]
机构：
[1] Huadong Med, Global Drug Dev Ctr, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.01.037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
28P
引用
收藏
页码：S14 / S14
页数：1
相关论文
共 47 条
  • [41] KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms (vol 27, pg 5697, 2021)
    Suzuki, Shinichiro
    Yonesaka, Kimio
    Teramura, Takeshi
    Takehara, Toshiyuki
    Kato, Ryoji
    Sakai, Hitomi
    Haratani, Koji
    Tanizaki, Junko
    Kawakami, Hisato
    Hayashi, Hidetoshi
    Sakai, Kazuko
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    CLINICAL CANCER RESEARCH, 2022, 28 (02) : 428 - 428
  • [42] KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms (vol 27, pg 5697, 2021)
    Suzuki, Shinichiro
    Yonesaka, Kimio
    Teramura, Takeshi
    Takehara, Toshiyuki
    Kato, Ryoji
    Sakai, Hitomi
    Haratani, Koji
    Tanizaki, Junko
    Kawakami, Hisato
    Hayashi, Hidetoshi
    Sakai, Kazuko
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 428 - 428
  • [43] A phase 1b study evaluating the combination of sotorasib, a KRASG12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC)
    Gandara, David
    Marrone, Kristen
    Govindan, Ramaswamy
    Skoulidis, Ferdinandos
    Durm, Gregory
    Clarke, Jeffrey
    Frank, Richard
    Krauss, John
    Snyder, Wendy
    Dai, Tian
    Mather, Omar
    Cifuentes, Paul
    Hindoyan, Antreas
    Anderson, Abraham
    Burns, Timothy
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [44] Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents
    Li, Ling
    Zhao, Huiting
    Liao, Hui
    Chen, Jingxuan
    Liu, Jin
    Chen, Jianjun
    BIOORGANIC CHEMISTRY, 2021, 110
  • [45] Structure-based drug discovery of MRTX1257: A selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer
    Marx, Matthew
    Baer, Brian
    Ballard, Joshua
    Blake, James
    Bouhana, Karyn
    Briere, David
    Burgess, Laurence
    Burkhard, Michael
    Chiang, Harrah
    Chicarelli, Mark
    Christensen, James
    Fischer, John
    Hallin, Jill
    Mejia, Macedonio
    Olson, Peter
    Savechenkov, Pavel
    Sudhakar, Niranjan
    Tang, Tony
    Vigers, Guy
    Fell, Jay
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [46] Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer.
    Marx, Matthew A.
    Baer, Brian R.
    Ballard, Joshua
    Blake, James F.
    Bouhana, Karyn
    Briere, David M.
    Burgess, Laurence E.
    Burkhard, Michael R.
    Chiang, Harrah
    Chicarelli, Mark J.
    Christensen, James G.
    Fischer, John P.
    Hallin, Jill
    Mejia, Macedonia J.
    Olson, Peter
    Savechenkov, Pavel
    Sudhakar, Niranjan
    Tang, Tony P.
    Vigers, Guy P.
    Fell, Jay B.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 67 - 68
  • [47] Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl} prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors
    Imaizumi, Tomoyoshi
    Shimada, Itsuro
    Satake, Yoshiki
    Yamaki, Susumu
    Koike, Takanori
    Nigawara, Takahiro
    Kaneko, Osamu
    Amano, Yasushi
    Mori, Kenichi
    Yamanaka, Yosuke
    Nakayama, Ayako
    Nishizono, Yoshihiro
    Shimazaki, Masashi
    Nagashima, Takeyuki
    Kuramoto, Kazuyuki
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 98
12345